Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Modality Treatment for Patients With Stage IV Melanoma: Cyclophosphamide and a Dendritic Cell Vaccine Loaded With Killed Allogeneic Melanoma Cells

NCT00313235 is registered in ClinicalTrials.gov with Baylor Research Institute as lead sponsor.

NCT NCT00313235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00313235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Modality Treatment for Patients With Stage IV Melanoma: Cyclophosphamide and a Dendritic Cell Vaccine Loaded With Killed Allogeneic Melanoma Cells
Lead sponsor
Baylor Research Institute
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2006
Completion date
June 30, 2012
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma stage iv